Other OTC USD

Hikma Pharmaceuticals PLC (HKMPF)

22.33 0.00 (0.00%)
As of April 17 at 9:49 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Engineer Said Samih Taleb Darwazah Executive Chairman 2.8M -- 1957
Mr. Riad Ali Mishlawi CEO & Director 1.1M -- 1964
Mr. Mazen Samih Taleb Darwazah Executive Vice Chairman & President of MENA 2.3M -- 1958
Mr. Khalid Waleed Hosny Al Nabilsi Chief Financial Officer -- -- 1972
Patricia Bousfield Chief Information Officer -- -- --
Mr. Guy Featherstone Associate Director of Investor Relations -- -- --
Mr. Samuel Park General Counsel -- -- --
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Executive Vice President of Corporate Development and M&A -- -- 1965
Mr. Hussein Omar Arkhagha Chief People Officer -- -- --
Ms. Susan Ringdal Executive Vice President of Strategic Planning & Global Affairs -- -- --

Hikma Pharmaceuticals PLC

1 New Burlington Place
London, W1S 2HR
United Kingdom
44 20 7399 2760 https://www.hikma.com
Sector: 
Healthcare
Full Time Employees: 
9,100

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Corporate Governance

Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 7; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 21, 2024
    Ex-Dividend Date
  • May 26, 2011
    Dividend Date

Upcoming Events